...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: relapse or late IRIS?
【24h】

Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: relapse or late IRIS?

机译:经治疗的HIV-1感染患者的肺隐球菌病,其病毒载量受到抑制,过去曾传播过隐球菌病:复发或晚期IRIS?

获取原文
获取原文并翻译 | 示例

摘要

Early initiation of combination antiretroviral therapy (cART) in AIDS presenters reduces mortality,1 but seems to worsen survival in cryptococcal meningitis, probably because of immune reconstitution inflammatory syndrome (IRIS), with fatal cerebral complications.2'3 Timing of cART initiation is not clearly defined, ranging from 2 to 10 weeks.4 Strategies aiming at reducing the risk of IRIS are lacking.We report a case of pulmonary and mediastinal lymph node cryptococcosis occurring late after immune reconstitution and fluconazole prophylaxis discontinuation in a patient with previous AIDS-presenting disseminated/meningeal cryptococcosis. A Pakistani man in his mid-forties presented with AIDS and disseminated/meningeal cryptococcosis (CD4 count 16 cells/mm3, plasma HIV-1 RNA 191100 copies/mL and blood and CSF cultures positive for Cryptococcus neoformans). He was treated with a standard amphotericin B course, followed by secondary fluconazole prophylaxis; cART was introduced 1 month later with co-formulated zidovudine/lamivudine and lopinavir/ritonavir, achieving virological suppression and immune restoration (Figure 1). The nucleoside backbone was switched to tenofovir/emtricitabine after 1 month, because of bone marrow toxicity (haemoglobin 8.3 g/dL, white blood cells 1910/mm3 and neutrophils 390/mm3).
机译:在AIDS主持人中尽早开始联合抗逆转录病毒疗法(cART)可以降低死亡率,1但似乎会使隐球菌性脑膜炎的生存恶化,这可能是由于免疫重建炎症综合症(IRIS)以及致命的脑部并发症引起的。2'3明确定义,范围为2到10周。4缺乏旨在降低IRIS风险的策略。我们报告了在先前有AIDS表现的患者中,免疫重建和氟康唑预防性停用后发生的肺和纵隔淋巴结隐球菌病病例播散/脑膜隐球菌病。一名四十多岁的巴基斯坦男子患有艾滋病和弥漫性/脑膜隐球菌病(CD4计数为16个细胞/ mm3,血浆HIV-1 RNA 191100拷贝/ mL,血液和CSF培养的新隐球菌为阳性)。用标准的两性霉素B疗程治疗他,随后进行氟康唑预防。 1个月后将cART与共同配制的齐多夫定/拉米夫定和洛匹那韦/利托那韦一起引入,实现了病毒学抑制和免疫恢复(图1)。 1个月后,由于骨髓毒性(血红蛋白8.3 g / dL,白细胞1910 / mm3和嗜中性粒细胞390 / mm3),核苷主链转换为替诺福韦/恩曲他滨。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号